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Abstract
Background: Constipation and diarrhoea are common complaints and often reported as adverse drug reactions.
This study aimed at finding associations between drugs and constipation and diarrhoea in a general population.
Methods: A selection of inhabitants in Oppland County, Norway participated in a cross-sectional survey.
Information about demographics, diseases including gastrointestinal complaints classified according to the Rome II
criteria and use of drugs were collected on questionnaires. Constipation was defined as functional constipation and
constipation predominant Irritable Bowel Syndrome (IBS), and diarrhoea as functional diarrhoea and diarrhoea
predominant IBS. Associations between drugs and constipation and diarrhoea were examined with multivariable
logistic regression models. Based on the multivariable model, the changes in prevalence (risk difference) of the
abdominal complaints for non-users and users of drugs were calculated.
Results: In total 11078 subjects were invited, 4622 completed the questionnaires, 640 (13.8%) had constipation and
407 (8.8%) had diarrhoea. To start using drugs increased the prevalence of constipation and diarrhoea with 2.5%
and 2.3% respectively. Polypharmacy was an additional risk factor for diarrhoea. Use of furosemide, levothyroxine
sodium and ibuprofen was associated with constipation, and lithium and carbamazepine with diarrhoea. The
excess drug related prevalence varied from 5.3% for the association between ibuprofen and constipation to 27.5%
for the association between lithium and diarrhoea.
Conclusions: Use of drugs was associated with constipation and diarrhoea in the general population. The
associations are most likely adverse drug reactions and show that drug-induced symptoms need to be considered
in subjects with these complaints.
Background
Constipation and diarrhoea are worldwide complaints
with some variations between geographical regions,
populations and definitions [1-7]. The use of drugs is
common, increases with age and has increased over
time with a doubling of prescriptions to elderly from
1996 to 2006 [8,9]. Unfortunately, drugs are associated
with adverse drug reactions (ADRs) which increase with
polypharmacy [3,10-16]. Gastrointestinal complaints like
constipation and diarrhoea are common ADRs [16-18].
The reported prevalence rates of gastrointestinal ADRs,
especially constipation and diarrhoea, are based mainly
on clinical drug trials and observational studies in
selected, often elderly, populations, and use heteroge-
neous definitions of constipation and diarrhoea
[3,11,14,17,18]. The prevalence of constipation and diar-
rhoea related to everyday use of drugs in an unselected
general population is in large unknown.
Increased knowledge about ADRs allows individual
adjustment of drug treatment in patients with gastroin-
testinal symptoms. This population based cross-sectional
study aimed at finding associations between drugs and
constipation and diarrhoea.
Methods
Participants
In 2001, all persons in Oppland County, Norway, born in
1970, 1960, 1955, 1940 and 1925, were invited to a health
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Design
The study was population-based with a cross-sectional
design. No remuneration was given. At attendance,
standardized questionnaires were completed and a phy-
sical examination was performed. All subjects were
asked to take home, complete and return by post a sup-
plementary questionnaire about the complaints. Non-
responders received two reminders.
Variables
Questionnaires
All participants filled in detailed questionnaires with
information about age, gender, height, weight, cohabit-
ing, years of education, physical activity (rated less than
1 hour/week, 1-2 hours/week and more than 3 hours/
week), number of cups of coffee per day, use of alcohol
(8 point ordinal scale from 1 = “never” to 8 = “4-7
times/week”) and smoking habits (never, past, current).
All present and previous diseases were noted. Musculos-
keletal complaints the last four weeks were assessed for
six locations (neck/shoulder, arms/hands, upper back,
lower back, hip/legs/feet and other locations) and the
intensity for each of them was rated as none, mild or
severe. A musculoskeletal complaints score was calcu-
lated by multiplying number of locations and intensity
giving a score with range 0-12. Mood disorders (mainly
anxiety and depression) were measured with Hopkins’
Symptom Check List-10 (HSCL-10) with range 1.0-4.0
and 1.85 as upper normal limit [20]. The subjects gave a
w r i t t e nr e p o r to na l ld r u g su sed regularly the last four
weeks. The questionnaires have been translated into
Norwegian, validated and extensively used in national
surveys by the Norwegian Institute of Public Health
[19]. Gastrointestinal complaints were assessed with a
q u e s t i o n n a i r eb a s e do nt h eR o m eI Ic r i t e r i af o rf u n c -
tional gastrointestinal disorders [21]. This survey has
previously been used for the study of the prevalence, co-
morbidity and impact of irritable bowel syndrome [22].
Definition of constipation and diarrhoea
The gastrointestinal symptom questionnaire allowed
classification of the disorders into functional constipa-
tion, functional diarrhoea and Irritable Bowel Syndrome
(IBS) with the subgroups diarrhoea predominant, consti-
pation predominant and alternating, in accordance with
t h eR o m eI Ic r i t e r i a[ 2 1 ] .I nt h i ss t u d y ,c o n s t i p a t i o n
includes functional constipation and constipation predo-
minant IBS, and diarrhoea includes functional diarrhoea
and diarrhoea predominant IBS.
Classification of drugs
Drug substances were classified according to the Anato-
mical-Therapeutic-Chemical Classification System
(ATC) at level 5 and as group of drugs at ATC level 4
[23]. Use of drugs was measured as yes/no (Yes = use of
one or more drugs), as number of drugs and on a cate-
gorical scale (0 = no drugs, 1 = use of one drug, 2 = use
o f2 - 3d r u g s ,a n d3=u s eo f> 3d r u g s ) .P o l y p h a r m a c y
was defined as using more than three drugs.
Analyses were performed for individual drugs (ATC-
l e v e l5 )a n dg r o u p so fd r u g sa tA T Cl e v e l4 ,w h i c ha r e
rather similar and probably have concurrent ADRs.
However, no analyses were performed for drugs used
for gastrointestinal disorders (ATC-classes A02, A03,
A06 and A07) since drug related gastrointestinal symp-
toms could not be distinguished from the disorder
under treatment. Nor were drugs or groups of drugs
used by less than 10 persons analysed.
Statistics
Bivariate analyses of the association between the abdom-
inal complaint and one variable at a time were analysed
with Student’s t-test, Wilcoxon-Mann-Whitney’s test, or
Fisher’s exact test (Tables 1 and 2). In multivariable
logistic regression models with abdominal complaint as
outcome, the effects of drugs were adjusted for covari-
ates selected as follows: Candidate covariates were all
background variables listed in Table 1. Forward likeli-
hood ratio (LR) selection with p-enter = 0.15 and
p-remove = 0.20 was followed by backwards LR with
p-enter = 0.05 and p-remove = 0.06, a procedure
adapted from Hosmer and Lemeshow [24]. Age and
gender were included in all models. Separate analyses
were performed for drug use no/yes (Table 3), number
of drugs (Table 4), and drug substances (Table 2). Can-
didate drug substances (for Table 5) were those with
unadjusted p-values ≤ 0.2 and groups of drugs with
p-value ≤0.2 if none of the substances in the group were
candidates. Based on the multivariable model, we esti-
mated the average change in prevalence (also called
average risk difference) of the abdominal complaint for
non-users and users of drugs and the separate drug sub-
stances, if they would start or stop using the drugs [25].
Unlike in randomized controlled trials, the characteris-
tics of users and non-users of the drugs differ. Hence,
the effect of the drug in terms of risk difference is not
the same among users and non-users of the drug. The
two risk differences are estimated using the method of
Bender et al [26].
Two-sided p-values ≤ 0.05 were regarded as statisti-
cally significant. Due to hypotheses testing for many
substances, p-values above 0.01 should be interpreted
with caution. We report 95% confidence intervals (CI)
where appropriate. The analyses were performed in
SPSS 16. The SPSS code “nne_ein.sps” available at Ralf
Bender’s software page was used for calculating change
in prevalence [26].
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This survey was approved by the Regional Committee
for Medical Research Ethics and the Data Inspectorate,
Oslo, Norway, and performed in accordance with the
Declaration of Helsinki.
Results
Participants
Out of 11078 subjects invited to the health survey, 6141
participated. In the participants and non-participants the
proportions of women was 55% and 45% respectively,
and mean age was 49.2 and 45.0 years respectively.
The gastrointestinal questionnaire was completed by
4622 of the participants, 640 (13.8%) had constipation
and 407 (8.8%) had diarrhoea. Two patients had both
constipation and diarrhoea (diarrhoea was probably
induced by use of laxatives). The responders were
more likely to be women than the non-responders
were (56% and 51% respectively), and younger (mean
age 48.9 and 50.1 years respectively). Figure 1 shows
the subjects in the study and the classification of func-
tional gastrointestinal disorders in more detail. Table 1
presents the characteristics of all participants and of
participants with constipation and diarrhoea, and gives
comparisons between those with and without constipa-
tion and with and without diarrhoea. Age, gender,
body mass index, use of alcohol, osteoporosis, muscu-
loskeletal complaints, mood disorders, use of drugs
and number of drugs were highly significantly asso-
ciated with constipation; and smoking, musculoskeletal
complaints, mood disorders, use of drugs and number
of drugs with diarrhoea.
Table 1 Characteristics of all participants (independent of complaints), participants with constipations and participants
with diarrhoea, and comparisons between subjects with and without diarrhoea and with and without constipation
Characteristics All participants
n = 4622
Participants with
constipation
n = 640
Participants with
diarrhoea
n = 407
Age (years) 49.4 (13.8) 52.2 (15.1)*** 50.7 (13.7)†
Gender (male) (%) 43.6 21.3*** 50.4**
Body mass index (kg/m
2) [0.2%] 26.9 (4.2) 26.1(4.1)*** 27.2 (4.1)*
Cohabiting (%) [14.9%] 89.3 87.9 86.2*
Years of education [1.0%] 12.2 (3.5) 12.0 (3.5) † 11.7 (3.4) *
Physical activity (breathless) (%) [7.2%] <1 hr/1-2 hrs/>3 hrs a
week
58.8/27.0/14.2 60.9/27.7/11.4 * 60.6/26.9/12.5
Cups of coffee/day [1.0%] 3.7 (2.8) 3.4 (2.6) * 3.8 (2.9)
Frequency of use of alcohol ¤ [0.8%] 4.4 (1.7) 4.1 *** (1.7) 4.6 * (1.7)
Use of alcohol >1 time/week (%) 10.6 8.2 * 12.9 †
Smoking habits (%) [0.6%] Never/Past/Current 44.5/27.2/28.3 46.1/27.4/26.5 35.9/31.4/32.7 ***
Asthma (%) [2.1%] 8.7 10.6 * 9.8
Allergic rhinitis (%) [15.4%] 12.9 13.6 13.5
Bronchitis (%) [3.5%] 2.5 2.7 2.5
Diabetes (%) [2.5%] 2.1 3.3 * 3.4 †
Osteoporosis (%) [3.3%] 2.4 4.7 *** 3.7 †
Myocardial infarction (%) [2.4%] 2.8 2.8 3.7
Angina pectoris (%) [2.4%] 3.7 6.1 * 4.2
Cerebral stroke (%) [2.5%] 2.0 3.1 * 3.7 *
Epilepsy (%) [0.8%] 1.6 2.4 † 1.7
Multiple sclerosis (%) [4.0%] 0.5 1.5 ** 0.7
Musculoskeletal complaints § 2.2 (2.2) 2.6 (2.4) *** 2.7 (2.4) ***
HSCL 10 # [6.4%] 1.3 (0.4) 1.4 (0.5) *** 1.4 (0.5) ***
Use of drugs (Yes) (%) 62.5 72,5 *** 70.3 ***
Number of drugs 1.34 (1.56) 1.64 (1.67) *** 1.70 (1.78)***
Number of drugs (%) 0 drug/1 drug/2 or 3 drugs/≥4 37.5/28.3/24.5/
9.8
27.5/30.3/29.7/12.5*** 29.7/29.0/25.8/15.5***
The results are given as number of subjects, proportion (in percentage) or mean (with SD in brackets) and the proportion of missing data to each questioni n
square brackets.
† = p < 0.20; * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
¤ Frequency of use of alcohol: 8 point ordinal scale: 1 = never used to 8 = 4-7 times a week.
§ Musculoskeletal complaints: Sum score (six location and intensity) 0-12.
# HSCL 10: Hopkins Symptom Check List 10 (Mood disorders) 1-4.
Fosnes et al. BMC Clinical Pharmacology 2011, 11:2
http://www.biomedcentral.com/1472-6904/11/2
Page 3 of 9Use of drugs and associations with constipation and
diarrhoea
In all, 288 different generic drugs were used, 252 after
exclusion of drugs for gastrointestinal disorders. After
exclusion of drugs and groups of drugs used by <10 per-
sons, 98 substances (ATC-level 5) and 20 groups at
ATC-level 4 were included in the analyses.
The mean number of drugs per person was 1.34
(range 0-9), and 2891 (62.5%) used one or more drugs.
Use of drugs was associated with constipation and diar-
rhoea, the unadjusted ORs were 1.69 and 1.46 respec-
tively (p ≤ 0.001), and likewise, adjusted OR were 1.30
(p = 0.012) and 1.37 (p = 0.011). Table 3 gives indepen-
dent predictors of constipation and diarrhoea.
Table 4 shows the association between numbers of
drugs and constipation and diarrhoea. Using more than
one drug was not associated with constipation over that
of one drug alone. However, polypharmacy increased
the prevalence of diarrhoea significantly, compared with
using one drug and 2-3 drugs the ORs were 1.46 (CI
1.01 to 2.10, p = 0.042), and 1.47 (CI 1.03 to 2.11, p =
0.034) respectively.
Drug substances associated with constipation and
diarrhoea
Drugs and group of drugs associated with constipation
and diarrhoea with p≤0.05 in bivariate analyses are listed
in table 2. In addition, 15 and 12 drugs were associated
with constipations and diarrhoea respectively with
p≤0.20. Three drugs were independent predictors of
constipation: furosemide (OR 2.16, CI 1.14 to 4.10, p =
0.019), levothyroxine sodium (OR 1.55, CI 1.04 to 2.31,
p = 0.033) and ibuprofen (OR 1.54, CI 1.17 to 2.03, p =
0.002), and two with diarrhoea: lithium (OR 6.09, CI
1.73 to 21.48, p = 0.005) and carbamazepine (OR 4.07,
CI 1.52 to 10.89, p = 0.005) (logistic regression analyses
with correction for the independent predictors given in
table 3). No groups of drugs at ATC-level 4 were inde-
pendent predictors of constipations or diarrhoea without
one substance in the group being associated with the
disorders.
Table 5 gives the observed prevalence of constipation
and diarrhoea for users and nonusers of drugs and for
drugs significantly associated to the complaint, the cal-
culated prevalence if users stop and nonusers start treat-
ment and the change in prevalence when stopping and
starting treatment. To start using drugs would increase
t h ep r e v a l e n c eo fc o n s t i p a t i o na n dd i a r r h o e aw i t h2 . 5 %
and 2.3% respectively. The excess drug related preva-
lence varied from 5.3% for the association between ibu-
profen and constipation, to 27.5% for the association
between lithium and diarrhoea.
Discussion
Use of drugs was significantly associated with constipa-
tion and diarrhoea in this study in the general popula-
tion, as it has been in studies performed in general
practice, in elderly and in other settings [3,7,14,16,18].
The prevalence of drug associated constipation and diar-
rhoea was judged as high (2.3% - 3.0%), particularly
Table 2 The prevalence of constipation and diarrhoea among users and non-users of drugs significantly associated
with the complaints (bivariate analyses, all participants)
ATC level ATC code Name of drug group/chemical substance Prevalence (%) Users/non users Statistics (p-value)
Constipation Level 4 C10AA HMG CoA reductase inhibitors 18.5/13.6 0.033
M01AE Propionic acid derivatives 18.7/13.3 0.001
N06AA Non-selective monoamine reuptake inhibitors 23.2/13.7 0.050
Level 5 C01AA04 Digitoxin 38.5/13.8 0.025
C01DA02 Glyceryl trinitrate 27.3/13.7 0.015
C03CA01 Furosemide 29.2/13.6 0.001
C10AA05 Atorvastatin 21.4/13.7 0.037
G03CX01 Tibolone 40.0/13.8 0.038
H03AA01 Levothyroxine sodium 28.1/13.4 <0.001
M01AE01 Ibuprofen 19.4/13.3 0.001
Diarrhoea Level 4 C10AA HMG CoA reductase inhibitors 12.7/8.6 0.031
R06AD Phenothiazine derivatives 28.6/8.7 0.029
Level 5 A10BA02 Metformin 30.8/8.7 0.022
C03EA01 Hydrochlorothiazide and potassium-sparing agents 25.0/8.7 0.009
C07AB02 Metoprolol 13.3/8.6 0.026
N03AF01 Carbamazepine 25.0/8.7 0.009
N05AN01 Lithium 33.3/8.7 0.017
N06AB05 Paroxetine 19.6/8.7 0.012
R03BA01 Beclometasone 28.6/8.7 0.029
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A D R s[ 2 7 ] .I ti st oe x p e c tt h a ts u b j e c t sw i t hA D R s
reduce or stop treatment, or switch to alternatives to
avoid the complaints, and thereby reduce the prevalence
of ADRs. However, it is likely that some subjects are
unaware of the connection between the complaints and
the drug. The results indicate an unfavourable effect of
everyday use of drugs on constipation and diarrhoea in
the general population. Changes in drug therapy might
be the most important easily susceptible factor to influ-
ence on in subjects with these disorders.
Polypharmacy is a risk factor for ADRs in general, and
especially among the elderly [3,10-15]. This study
showed, however, only an association between polyphar-
macy and diarrhoea. One possible explanation of the
difference between constipation and diarrhoea is that
more drugs are associated with diarrhoea than with
constipation.
As expected, several drugs were associated with consti-
pation and diarrhoea in bivariate analyses (table 2), but the
number of specific drugs associated with constipation and
diarrhoea in multivariable analyses was lower than
expected: three and two respectively. Constipation has
been mentioned as an ADR to both furosemide and ibu-
profen in some reports and high quality information about
marketed drugs [7,16,28]. The pathophysiology is uncer-
tain. Dehydration might cause constipation in users of fur-
osemide, and inhibition of prostaglandins might explain
constipation in ibuprofen users since prostaglandin analo-
gues cause diarrhoea [29]. Diarrhoea has been related to
too high doses of levothyroxine sodium, constipation has
not [28]. Since severe hypothyroidism is associated with
constipation, the association between levothyroxine
sodium and constipation might have been confounded by
the disorder under treatment (hypothyroidism) or insuffi-
cient treatment, or it might be a type I error. Carbamaze-
pine and lithium were both associated with diarrhoea,
which is a known ADR to these drugs [28]. The excess
prevalence in users was surprisingly high (19 and 27%
respectively), particularly for lithium because gastrointest-
inal ADRs are expected to level off and/or decline with
continuous use [30]. The fact that it might be undesirable
to change lithium therapy if the effect is satisfactory could
explain the high ADR rate. In all, the excess prevalence of
constipation and diarrhoea associated with these five
drugs was high (5-27%) related to the authorities definition
of an ADR as common if the prevalence is between 1-10%
[31]. The Rome II definition of constipation and diarrhoea
includes mild and intermittent symptoms, which might be
Table 3 Independent predictors for constipation and
diarrhoea
Independent
predictor
OR
Estimates 95% CI p-value
Constipation Use of drug 1.30 1.06 to
1.59
0.012
Gender (women) 3.24 2.61 to
4.02
<0.001
Age (years) 1.01 1.003 to
1.02
0.005
BMI (body mass index) 0.95 0.93 to
0.97
<0.001
Frequency of use of
alcohol
0.94 0.89 to
0.99
0.024
Musculoskeletal
complaints
1.04 1.002 to
1.09
0.042
Angina pectoris 1.86 1.21 to
2.85
0.004
Multiple sclerosis 2.41 1.03 to
5.66
0.043
Diarrhoea Use of drugs 1.37 1.08 to
1.74
0.011
Gender (Women) 0.69 0.55 to
0.86
0.001
Age (years) 0.999 0.99 to
1.01
0.824
(ns)
Frequency of use of
alcohol
1.10 1.03 to
1.17
0.006
Years of education/
schooling
0.96 0.93 to
0.995
0.023
HSCL 10 (Mood
disorders)
1.70 1.37 to
2.11
<0.001
Osteoporosis 2.20 1.21 to
3.97
0.009
Multivariable logistic regression analyses with stepwise selection of variables.
Use of drugs and not the individual drugs were included in the models. Age
and gender were included in the models independent of significance.
Table 4 Number of drugs as predictors for constipation
and diarrhoea
Number of drugs OR
Estimates 95% CI p-value
Constipation None 1.00
Using one drug 1.34 1.07 to
1.69
0.012
Using two or three
drugs
1.26 0.99 to
1.61
0.062
Using four or more
drugs
1.21 0.85 to
1.71
0.288
Diarrhoea None 1.00
Using one drug 1.31 0.995 to
1.73
0.055
Using two or three
drugs
1.30 0.96 to
1.75
0.087
Using four or more
drugs
1.91 1.31 to
2.78
0.001
Multivariable logistic regression analyses - adjusted for significant predictors.
Significant predictors for constipation: Age, gender, BMI, frequency of use of
alcohol, musculoskeletal complaints, angina and multiple sclerosis.
Significant predictors for diarrhoea: Age, gender, frequency of use of alcohol,
years of education, mood disorders and osteoporosis.
Fosnes et al. BMC Clinical Pharmacology 2011, 11:2
http://www.biomedcentral.com/1472-6904/11/2
Page 5 of 9missed in clinical trials. Therefore, the clinical relevance of
the findings is uncertain, but calls attention to these drugs
in patients bothered by constipation and diarrhoea. The
overall prevalence of constipation and diarrhoea in this
study (13.8% and 8.8% respectively) was of the same order
as reported in other studies using the same definitions
(13.1-20.3% and 13.5% respectively) [5,6].
Other drugs known to be associated with constipation
(such as iron, codein (opiates), calcium channel blockers,
anticholenergic drugs, anticonvulsant drugs, anti-
parkinson drugs, and antipsychotics) and diarrhoea (such
as antibiotics, NSAID, psycholeptics, selective serotonin
reuptake inhibitors and antihypertensives) did not show
significant associations with constipation and diarrhoea in
this study [3,7,16,18]. Some of them were significantly
associated in the bivariate analyses (table 2) but not in the
multivariable analyses. It shows the importance of prag-
matic studies in the general population, and that such stu-
dies differ from traditional clinical trials. Reasons could be
dose reduction or reduced compliance when ADRs occur,
waning symptoms during long-term treatment, switching
to other drugs without ADR, or a type II error.
Other predictors for constipation and diarrhoea were
overall in accordance with other reports. There was a pre-
dominance of females with constipation and males with
diarrhoea [4,5,7,16]. Constipation increased with age and
seemed to be related to inactivity, coronary disease and
neurological diseases [4,7,16,32]. The association between
diarrhoea and mood disorders has been reported in other
studies, whereas the associations to low education and
osteoporosis remain unexplained [33].
Strengths and weaknesses
Unlike most reports on ADRs, this study describes asso-
ciations between drugs and symptoms related to every-
day use of drugs in the general population. The design
avoids problems related to clinical trials and surveys in
selected, often elderly, populations. Except for the possi-
bility that “trained complainers” were more prone to
respond, there was no selection bias or loss to follow
up, compliance and reporting of complaints were unaf-
fected by the personnel’s interest in the reports, and the
treatment duration was probably longer than in most
clinical trials. It is not known how the drugs were used,
and incorrect use might increase ADRs. However, these
results reflect associations related to everyday use of
drugs, used correctly or not, but the cross sectional
design gives no information about causality.
The ATC-classification of drugs used in this study
relates ADRs to specific chemical compounds or groups
with similar chemical compounds, which is a strength
[23]. Most studies relate ADRs to broader and poorly
defined groups of drugs e.g. antipsychotics and antihista-
mines, which are groups containing drugs with different
A D R s ,a n dt h e r e f o r eg i v ei n s u fficient information about
ADRs related to each compound.
Table 5 Observed prevalence (in per cent) of constipation and diarrhoea in users and non-users of drugs, calculated
prevalence if treatment is stopped or started, and changes of prevalence (average risk difference) with 95% CI when
stopping and starting treatment (multivariable analyses, 4586 and 4268 cases available for the analyses of
constipation and diarrhoea respectively)
Abdominal
complaint
Predictor Observed
prevalence in
nonusers
Calculated prevalence
if starting treatment
Increased
prevalence
(95% CI)
Observed
prevalence in
users
Calculated prevalence
if stopping treatment
Reduced
prevalence
(95% CI)
Constipation Use of drugs 10.2 12.7 2.5 15.9 12.8 3.0
(0.6 to 4.4) (0.7 to 5.3)
Furosemide 13.5 24.3 10.7 28.6 16.5 12.1
(0.0 to 21.5) (0.6 to
23.6)
Levothyroxine
sodium
13.3 18.7 5.4 26.8 19.5 7.3
(-0.2 to
11.1)
(0.0 to
14.6)
Ibuprofen 13.1 18.4 5.3 19.8 14.0 5.8
(1.6 to 9.1) (1.7 to 9.8)
Diarrhoea Use of drugs 7.1 9.5 2.3 10.2 7.7 2.5
(0.6 to 4.1) (0.7 to 4.3)
Lithium 8.9 36.2 27.2 36.4 8.9 27.5
(-0.7 to
55.1)
(-0.6 to
55.5)
Carbamazepine 8.9 27.7 18.8 28.6 9.4 19.2
(-0.1 to
37.7)
(0.3 to
38.1)
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the estimated changes in prevalence of the complaints
when non-users start and users stop treatment. Unlike
in randomized controlled trials, the distribution of cov-
ariates in subjects using and not using the drug differs.
These risk differences are estimated taking into account
differences in background variables among users and
non users of the drug, as well as uncertainties in the
estimates for the background variables [25]. This is a
clinically more meaningful measure than OR.
The low response rate, 42% of all invited and 75% of
the participants in the health survey might reduce the
No abdominal pain / discomfort   
N = 3765     
81.5% 
Abdominal pain / discomfort 
N = 857        
18.5% 
Answered the GI-questionnaire 
N = 4622 
The study population  
Participated in the health survey            
N = 6141 
Invited to the health survey,  
Oppland County  
N = 11078 
Did not participate in the 
survey N = 4937 
Did not answer the GI-
questionnaire N = 1519 
Functional constipation 
N = 537 
11.6% 
Constipation 
N = 640 
13.8% 
IBS – constipation 
N = 103 
2.2% 
Functional diarrhoea 
N = 296 
66.4% 
Diarrhoea 
N = 407 
8.8% 
IBS – diarrhoea 
N = 111 
2.4% 
IBS – alternating 
N = 174 
3.8% 
Irritable 
bowel 
syndrome 
(IBS) 
N = 388 
8.4%
Figure 1 Flow chart of the participants in the study with indication of complaints. The study focuses on the groups with constipation
(N = 640) and diarrhoea (N = 407).
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Page 7 of 9external validity. However, analyses of a similar study
conducted by Norwegian Institute of Public Health in
2001 with a response rate of 46% showed no impact of
the low response rate on self-selection [34].
T h es i z eo ft h es t u d ya l l o w so n l yd e m o n s t r a t i o no f
common ADRs. Common ADRs are defined by the
authorities as prevalence rates between 1-10% [31]. The
power of the study was 80% to detect an adverse event
with a prevalence of 1%, given that 5% of the partici-
pants use the drug (a = 0.05). Clinically relevant infor-
mation about individual drugs might have been missed
since most drugs were used by less than 1% of the
population.
The temporal relationship between drugs and symp-
toms in this study is uncertain. The questionnaire asked
for symptoms last 3 months and use of drugs last
4 weeks. However, the temporal relationship is probably
a minor problem since symptoms according to the
Rome criteria are long lasting and regularly used drugs
are most often long-term treatment.
Because the participants were asked for regularly used
drugs the last four weeks, information about compli-
a n c e ,o v e rt h ec o u n t e rd r u g s ,d r u g st a k e nt or e l i e v e
symptoms, drugs taken on demand, general life style
and food habits are insufficient. Analgesics (e.g. with
codein and acetylsalicylic acid) and other drugs that
influence on gastrointestinal function might therefore
have been left out, and irregular and therefore not regis-
tered intake of laxatives and anti-diarrhoeas might have
reduced the prevalence of the complaints. Therefore, the
associations between drugs and the complaints do not
prove, but only indicate causality.
Conclusions
Everyday use of drugs was associated with an increased
prevalence of constipation and diarrhoea, and polyphar-
macy with an additional risk of diarrhoea in the general
population. Furosemide, levothyroxine sodium and ibu-
profen were significantly associated with constipation,
and carbamazepine and lithium with diarrhoea. The
associations do not prove, but indicate that constipation
and diarrhoea are common ADRs. In patients with con-
stipation or diarrhoea, drug induced symptoms need to
be considered and changes in drug regimens performed
along with other interventions.
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